Nature Communications (Aug 2016)
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- Jeffrey J. Wallin,
- Johanna C. Bendell,
- Roel Funke,
- Mario Sznol,
- Konstanty Korski,
- Suzanne Jones,
- Genevive Hernandez,
- James Mier,
- Xian He,
- F. Stephen Hodi,
- Mitchell Denker,
- Vincent Leveque,
- Marta Cañamero,
- Galina Babitski,
- Hartmut Koeppen,
- James Ziai,
- Neeraj Sharma,
- Fabien Gaire,
- Daniel S. Chen,
- Daniel Waterkamp,
- Priti S. Hegde,
- David F. McDermott
Affiliations
- Jeffrey J. Wallin
- Genentech, Inc.
- Johanna C. Bendell
- GI Oncology Research, Drug Development Unit, Sarah Cannon Research Institute
- Roel Funke
- Genentech, Inc.
- Mario Sznol
- Department of Internal Medicine and Melanoma Unit, Yale Cancer Center
- Konstanty Korski
- Roche Diagnostics GmbH
- Suzanne Jones
- GI Oncology Research, Drug Development Unit, Sarah Cannon Research Institute
- Genevive Hernandez
- Genentech, Inc.
- James Mier
- Beth Israel Deaconess Medical Center
- Xian He
- Genentech, Inc.
- F. Stephen Hodi
- Dana-Farber/Brigham and Women’s Cancer Center
- Mitchell Denker
- Genentech, Inc.
- Vincent Leveque
- Genentech, Inc.
- Marta Cañamero
- Roche Diagnostics GmbH
- Galina Babitski
- Roche Diagnostics GmbH
- Hartmut Koeppen
- Genentech, Inc.
- James Ziai
- Genentech, Inc.
- Neeraj Sharma
- Genentech, Inc.
- Fabien Gaire
- Roche Diagnostics GmbH
- Daniel S. Chen
- Genentech, Inc.
- Daniel Waterkamp
- Genentech, Inc.
- Priti S. Hegde
- Genentech, Inc.
- David F. McDermott
- Beth Israel Deaconess Medical Center
- DOI
- https://doi.org/10.1038/ncomms12624
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 8
Abstract
Cancer immunotherapy can be used in combination with other therapies for a better response. Here, the authors conduct a phase Ib clinical study and report the clinical activity and the immune response of the anti-PDL1 agent, atezolizumab, in combination with bevacizumab in ten patients with metastatic renal cell carcinoma.
